Dental and DSO M&A Multiples Report 2026: Valuation Benchmarks by Size and Segment

Last updated: June 29, 2026. Coverage window: transactions closed 2019 through Q2 2026. Primary NAICS: 621210 (Offices of Dentists). Geography: United States.

Quick Answer

Key Findings

The following data points are each individually verified against a named source with an earnings basis, size band, vintage, and geography attached. Ranges are observed, not appraised.

1. Solo general practice under $500K SDE traded in a 4.0x to 6.0x SDE band in the year ending Q2 2026, per Provident Healthcare Partners‘ Q1 2026 Dental Services Sector Update (US practice sales, primary care GP).
2. Two-doctor group practices with $500K to $1.0M SDE traded in a 4.5x to 6.5x SDE band over the same window, per Provident Q1 2026 and Cain Watters Q2 2026 practice transition benchmarks.
3. Multi-location groups with $1.0M to $3.0M adjusted EBITDA (the classic DSO add-on target) traded in a 6.5x to 9.0x adjusted EBITDA band during 2024 through Q2 2026, per Skytale Group 2026 Dental M&A Report and Provident DSO commentary.
4. Regional multi-site groups with $3.0M to $10.0M adjusted EBITDA traded in an 8.0x to 11.0x adjusted EBITDA band during 2024 through Q2 2026, per Skytale and Provident.
5. Platform-tier DSO targets with $10.0M or greater adjusted EBITDA traded in a 10.0x to 15.0x adjusted EBITDA band during 2024 through Q2 2026, per Skytale, Provident, and PitchBook DSO transaction summaries.
6. GF Data reported healthcare services segment multiples on completed private transactions between $10M and $500M enterprise value in the 6.0x to 9.5x TTM adjusted EBITDA range across 2023 through 2025, with dental sub-segment consistently at or above the healthcare median (GF Data Healthcare M&A Report, Q4 2025).
7. Orthodontics traded at roughly a 1.0 to 3.0 turn premium to comparable-sized general practice on adjusted EBITDA in 2024 through Q2 2026, per Provident orthodontic segment commentary and Group Dentistry Now transaction coverage.
8. Oral and maxillofacial surgery traded at roughly a 1.0 to 3.0 turn premium to comparable-sized GP on adjusted EBITDA over the same window, per Provident and Skytale segment reports; case-mix and out-of-network revenue drive intra-band variance.
9. Endodontics multi-site groups above $2M EBITDA traded in a 7.0x to 10.0x adjusted EBITDA band during 2024 through Q2 2026, per Provident and Skytale endodontic commentary; single-office endodontics traded closer to the specialty GP band.
10. Periodontics multi-site groups above $2M EBITDA traded in a 6.5x to 9.5x adjusted EBITDA band over the same window, per Provident perio commentary; single-office perio ranges were narrower and closer to general practice comparables.
11. Pediatric dentistry multi-site groups above $2M EBITDA traded in a 7.5x to 11.0x adjusted EBITDA band during 2024 through Q2 2026, per Provident pediatric segment commentary and Group Dentistry Now coverage.
12. Payer mix drove observed intra-band variance of roughly 1.0 to 2.0 turns. Fee-for-service dominant practices traded at the top of published ranges; Medicaid-heavy practices generally traded at the bottom, absent scaled unit economics (Cain Watters and Menke Group practice transition data, 2024 through Q2 2026).
13. The SBA 7(a) loan program continued to underwrite the majority of solo GP practice acquisitions under $5M project cost during 2025 through Q2 2026, per SBA 7(a) Lender Rankings and Coleman Report annual dental-vertical summaries.
14. Rollover equity between 10% and 30% of headline consideration was standard on DSO platform and add-on transactions above $5M enterprise value in 2024 through Q2 2026, per Provident and Skytale deal structure commentary.
15. The federal funds target range sat at 4.25% to 4.50% as of the June 2026 FOMC decision, per the Federal Reserve H.15 statistical release, providing the rate-environment context for the 2026 multiple band observations.

Multiples by Size Band (Spine)

Two overriding rules govern the size-band spine. First, SDE and adjusted EBITDA are not interchangeable earnings bases. SDE adds back a full owner-operator compensation package and is used for practices where the owner is the primary producer. Adjusted EBITDA reflects a management-run business and is used where the doctor is replaceable at market compensation. Second, the transition zone between the two bases sits between roughly $750K and $1.0M of adjusted earnings, and it is where valuation methodology most frequently breaks down for unsophisticated sellers.

Size-band spine table

Under $500K SDE (solo owner-operator GP)

Observed range: 4.0x to 6.0x SDE, TTM, year ending Q2 2026, US.
Sources: Provident Healthcare Partners Q1 2026 Dental Services Sector Update; Cain Watters Q2 2026 practice transition benchmarks; BizBuySell dental practice sales.
Buyer universe: individual dentists, small local groups.
Financing: SBA 7(a), local bank, seller note.

Owner-doctor generally produces 60% or more of collections at this size band. Retirement-driven sales dominate. Building lease terms and post-close owner clinical days are pricing levers. Practices with fewer than 900 active patients and above-market lease exposure landed in the lower half of the range. Practices with digital dentistry investment (cone beam CT, intra-oral scanner, in-house CAD/CAM) and clean lease assignment consent secured pre-marketing consistently landed in the upper half. The 2020 to 2022 comparable was roughly 3.75x to 5.75x SDE, with modest upward pressure at the upper end from DSO buyers reaching down for FFS-heavy targets during the platform peak.

$500K to $1.0M SDE (mature solo or two-doctor group)

Observed range: 4.5x to 6.5x SDE, TTM, year ending Q2 2026, US.
Sources: Provident Q1 2026; Cain Watters Q2 2026; Menke Group 2025 to 2026 dental practice sales data.
Buyer universe: individual dentists, small groups, occasional DSO add-on for FFS-heavy targets.

The upper end of this band was reached by practices with two producing doctors, FFS-dominant payer mix, digital dentistry investment, and lease terms with landlord assignment consent secured pre-marketing. SBA 7(a) remains the dominant financing structure at this size, with occasional DSO cash-and-note structures where the acquirer wants clean asset consolidation without a rollover component. The 2020 to 2022 comparable was roughly 4.5x to 7.0x SDE, with DSO buyers actively competing at the upper end during the platform peak.

$1.0M to $3.0M adjusted EBITDA (LMM multi-location group; DSO add-on target)

Observed range: 6.5x to 9.0x adjusted EBITDA, TTM, post normalization, year ending Q2 2026, US.
Sources: Skytale Group 2026 Dental M&A Report; Provident Q1 2026 DSO section; Group Dentistry Now transaction coverage.
Buyer universe: DSOs, PE add-on programs.
Financing: sponsor equity plus asset-based lending; frequent unitranche.

This is the classic DSO add-on band. Rollover equity of 15% to 30% is common. Buyers underwrite associate-doctor productivity, hygiene retention, and CAD/CAM utilization. QoE is typically required. Practices with three or more locations and $200K or more adjusted EBITDA per location traded in the upper half. The 2020 to 2022 comparable was roughly 7.5x to 10.0x adjusted EBITDA, reflecting the peak add-on window.

$3.0M to $10.0M adjusted EBITDA (regional multi-site group / DSO tuck-in)

Observed range: 8.0x to 11.0x adjusted EBITDA, TTM, post QoE normalization, year ending Q2 2026, US.
Sources: Skytale 2026; Provident Q1 2026; PitchBook DSO transaction summaries.
Buyer universe: DSOs, sponsor-backed platforms, occasional strategic buyers.
Financing: sponsor equity plus unitranche; occasional public debt.

Regional platforms with clean multi-site P&L, centralized RCM (revenue cycle management), and doctor-partnership programs traded in the upper half. Specialty overlay (in-house ortho, oral surgery, or endodontics) added roughly one turn on average. The 2020 to 2022 comparable was roughly 9.5x to 13.0x adjusted EBITDA. The 2026 band reflects tighter equity IRR underwriting and higher cost of debt relative to the peak.

$10.0M+ adjusted EBITDA (DSO platform target)

Observed range: 10.0x to 15.0x adjusted EBITDA, TTM, post full QoE, year ending Q2 2026, US.
Sources: Skytale 2026; Provident Q1 2026; PitchBook; Group Dentistry Now DSO M&A coverage.
Buyer universe: institutional sponsors, large DSOs (add-on to scaled platforms), occasional strategic.
Financing: sponsor equity plus committed debt package; frequent syndicated.

Platform-tier assets required proven de novo economics, doctor-recruiting pipeline, MSO architecture with CPOM compliance across footprint, and specialty diversification. Cleanest platforms with specialty exposure and 20%-plus organic growth cleared the top of the range. The 2020 to 2022 comparable was 12.0x to 16.0x adjusted EBITDA, with the range compressed roughly 2 to 3 turns from that peak in the current window.

Reading the spine table: ranges never blend SDE and adjusted EBITDA within the same row. Multiples are not appraisals. Individual outcomes vary based on drivers detailed below.

Multiples by Sub-Segment

Single-location general practice (SDE-based)

Observed range: 4.0x to 6.5x SDE, TTM, typically under $1.0M SDE, year ending Q2 2026, US.
Sources: Provident Q1 2026; Cain Watters Q2 2026; BizBuySell dental transactions; Menke Group.

The single-location GP is the largest deal-count segment in dental M&A. The buyer universe is a first-time buyer dentist, an associate transitioning to ownership, or a small local group. Location, lease term, patient count, and doctor production split drive intra-band variance. Practices with fewer than 900 active patients and over 30% Medicaid participation generally landed in the lower half. Practices with FFS-dominant payer mix, digital dentistry investment, and structured associate coverage generally landed in the upper half.

Multi-location group (2 to 10 sites, adjusted EBITDA)

Observed range: 6.5x to 10.0x adjusted EBITDA, TTM, post normalization, $1.0M to $10.0M adjusted EBITDA, year ending Q2 2026, US.
Sources: Skytale 2026; Provident Q1 2026; PitchBook DSO deal data.

The buyer universe converts from individual dentists to DSOs and sponsor-backed platforms at roughly $1.5M to $2.0M adjusted EBITDA. Centralized back office, associate-doctor retention, and de novo track record push multiples toward the top of the range. Practices without centralized RCM or with high owner-doctor concentration land in the lower half.

Specialty: Orthodontics

Observed range: 6.0x to 8.5x SDE (single-office solo owner); 7.0x to 11.0x adjusted EBITDA (multi-site above $2M EBITDA); year ending Q2 2026, US.
Observed premium vs GP baseline: roughly 1.0 to 3.0 turns above equivalent-sized GP on the matching earnings basis.
Sources: Provident orthodontic quarterly commentary; Skytale 2026; Group Dentistry Now ortho DSO coverage.

Orthodontics historically commanded a persistent premium over general practice due to elective, cash-pay, and contract-based revenue. Aligner and clear-tray adoption expanded the addressable market and pulled some volume from traditional wire-and-bracket cases. Ortho traded roughly 1.0 to 3.0 turns above equivalent-sized GP in 2024 through Q2 2026. Ortho-focused consolidator platforms competed alongside GP-focused DSOs at the upper end of the multi-site band.

Specialty: Oral and maxillofacial surgery (OMS)

Observed range: 6.5x to 9.0x SDE (single-office solo owner); 8.0x to 12.0x adjusted EBITDA (multi-site above $2M EBITDA); year ending Q2 2026, US.
Observed premium vs GP baseline: roughly 1.0 to 3.0 turns above equivalent-sized GP; the highest specialty premium in the vertical.
Sources: Provident OMS quarterly commentary; Skytale 2026.

OMS carried the highest per-doctor revenue among dental specialties, driven by implant, wisdom tooth extraction, and full-arch implant volume. Out-of-network revenue and case-mix drove intra-band variance. Full-arch implant capability was a distinct pricing lever. Practices with in-house 3D printing and same-day surgical guides commanded the top of the OMS multi-site band.

Specialty: Endodontics

Observed range: 5.5x to 7.5x SDE (single-office solo); 7.0x to 10.0x adjusted EBITDA (multi-site above $2M EBITDA); year ending Q2 2026, US.
Observed premium vs GP baseline: multi-site endodontics commanded roughly 0.5 to 1.5 turns above equivalent-sized GP on adjusted EBITDA; single-office ranges were narrower and closer to specialty GP comparables.
Sources: Provident endodontic commentary; Skytale 2026.

Endodontics is highly referral-flow dependent. Practices with three or more producing endodontists and diversified referral sources traded higher. Single-office endodontics ranges were narrower than GP due to smaller buyer universe. This range is directional and carries lower confidence than the GP baseline given the sample-size constraint at the single-office level.

Specialty: Periodontics

Observed range: 5.0x to 7.0x SDE (single-office solo); 6.5x to 9.5x adjusted EBITDA (multi-site above $2M EBITDA); year ending Q2 2026, US.
Observed premium vs GP baseline: multi-site periodontics landed roughly at or modestly above equivalent-sized GP on adjusted EBITDA, with implant-heavy perio pulled toward OMS ranges.
Sources: Provident perio commentary; Skytale 2026.

Periodontics benefits from implant-case revenue but faces the narrowest specialty buyer universe. Implant-heavy perio practices traded closer to OMS ranges. Traditional soft-tissue perio landed at the low end of the specialty band. As with endodontics, the single-office solo range is directional and reflects a small observed sample.

Specialty: Pediatric dentistry (pedo)

Observed range: 5.5x to 7.5x SDE (single-office solo); 7.5x to 11.0x adjusted EBITDA (multi-site above $2M EBITDA); year ending Q2 2026, US.
Observed premium vs GP baseline: multi-site pediatric commanded roughly 0.5 to 2.0 turns above equivalent-sized GP on adjusted EBITDA.
Sources: Provident pediatric commentary; Group Dentistry Now pedo consolidator coverage.

Pediatric dentistry benefits from recurring visit cadence, long patient tenure, and family referral dynamics. Medicaid participation is materially higher in pedo than in adult GP, and Medicaid mix drove intra-band variance. Pedo DSO consolidation was among the most active sub-verticals through 2024 and 2025, with several named pediatric-focused platforms actively adding on to existing footprints.

DSO-affiliated (platform-quality, adjusted EBITDA)

Observed range: 10.0x to 15.0x adjusted EBITDA, TTM, post full QoE, $10.0M+ adjusted EBITDA, year ending Q2 2026, US.
Sources: Skytale 2026; Provident Q1 2026; PitchBook DSO transaction summaries; Group Dentistry Now DSO M&A coverage.

Platform DSOs are typically MSO-structured under CPOM-restrictive states. Management fee mechanics are a due diligence topic. Multiples in the top of the range required proven de novo economics, doctor-recruiting pipeline, specialty diversification, and platform-level EBITDA growth. Named DSO context appears below for buyer-universe orientation only.

Specialty premium ladder table

Named DSO context (public commentary only, no transaction multiples asserted)

The following named platforms are cited from publicly reported ownership disclosures for buyer-universe orientation only. Transaction multiples on these named platforms are not publicly disclosed and are not asserted in this report.

• Heartland Dental is majority-owned by KKR since 2018. Heartland is the largest DSO by supported office count, with approximately 1,900 offices reported in company press. It operates under a support-services model with individual doctor-owner practice equity.
• Aspen Dental Management is majority-owned by Leonard Green & Partners. It is one of the largest dental care networks by patient count in the US.
• Smile Brands is majority-owned by Gryphon Investors following the 2019 acquisition from Freeman Spogli.
• Pacific Dental Services is one of the largest privately held DSOs and reports founder-family ownership.
• ClearChoice is a specialty-focused (implant and full-arch) DSO majority-owned by Sentinel Capital Partners since 2020, per company press.
• MB2 Dental received a Warburg Pincus investment. MB2 has been widely covered by Group Dentistry Now as an active mid-market DSO consolidator.
• North American Dental Group was acquired by The Jordan Company. NADG has been widely covered by Modern Healthcare and Group Dentistry Now.
• Dental Care Alliance has been publicly reported as a Mitsui-affiliated platform in trade press coverage. It is among the most-cited multi-region GP-focused platforms.
• Great Expressions Dental Centers is a multi-region DSO reported in Modern Healthcare and Group Dentistry Now coverage as a sponsor-owned platform.
• Sage Dental Management has been reported as a Southeast-focused platform with sponsor investment and continued M&A activity through 2024 and 2025.
• American Dental Partners is a longstanding management services organization structure with public reporting history predating the modern DSO taxonomy.
• Specialty-focused platforms: beyond ClearChoice in implants and full-arch, the orthodontic consolidator category includes Smile Doctors (Thomas H. Lee Partners majority reported), widely cited in Group Dentistry Now coverage of the ortho DSO segment through 2024. Pediatric-focused platforms including Kids Dental Kare and Rock Dental Brands have appeared in trade press coverage of pediatric DSO consolidation.

Named ownership is included for buyer-universe orientation. Multiples on specific named private transactions are not asserted where they are not publicly disclosed. The named-platform list is not exhaustive; the DSO taxonomy includes over one hundred platforms in Group Dentistry Now’s ongoing DSO census through 2025, with the top ten platforms accounting for a large share of supported office count and the long tail composed of regional and sub-regional platforms.

What Moves the Multiple (Drivers)

The following drivers are the most frequently cited by Provident, Skytale, Cain Watters, and Menke Group in their 2024 through Q2 2026 practice transition commentary. Each driver is a directional lever, not a formula.

Payer mix (fee-for-service vs PPO vs Medicaid)

Fee-for-service dominant practices traded above PPO-heavy practices of the same size and specialty. PPO participation depth (number of networks, in-network write-off percentage) shaped the mid-band. Medicaid-heavy practices generally traded one to two turns below FFS-matched comparables, absent scaled Medicaid-focused unit economics. Cain Watters and Menke Group both cite payer mix as the single largest driver of intra-band variance at the practice level.

A practical taxonomy for 2024 through Q2 2026:

• Above 60% FFS collections: generally landed in the upper half of published ranges.
• 30% to 60% FFS with the balance in PPO participation: generally landed in the mid-band.
• Under 30% FFS and heavy PPO participation across multiple networks: generally landed in the lower half of published ranges.
• 40% or greater Medicaid collections: generally compressed one to two turns below FFS-matched comparables, with narrower ranges reflecting a smaller buyer universe.

State Medicaid dental fee schedule variance is material. States with above-average Medicaid dental reimbursement see less multiple compression from high Medicaid mix than states with the lowest Medicaid dental fee schedules. The ADA Health Policy Institute publishes state-level Medicaid dental fee schedule data that dental M&A advisors and buyer diligence teams typically consult during payer-mix normalization.

Insurance participation depth

Open-network practices with a small number of contracted PPOs traded at a premium to practices contracted with a wide PPO network. Provident’s Q1 2026 commentary specifically highlights write-off percentage as a due diligence line item; write-off percentages above roughly 35% of gross production consistently landed practices in the lower half of published ranges. This is because a high write-off percentage reflects both PPO negotiated fee compression and, frequently, a legacy fee schedule that has not been updated to reflect current market rates.

Recurring revenue: hygiene, membership plans, and orthodontic contract length

Recurring revenue at the dental practice level is defined by hygiene visit frequency, membership or dental savings plan penetration, and orthodontic contract length. Practices with over 55% of collections from hygiene and preventive care, or with membership plan penetration above 10% of the active patient base, tended to price at the upper end of size-matched ranges. Practices with hygienist tenure above 4 years and active recall program compliance consistently landed above the mid-band. Skytale 2026 flags hygiene retention as an increasingly explicit line item in platform-tier QoE work.

Doctor concentration and owner-doctor dependence

Owner-doctor concentration is the mirror of the recurring-revenue driver. Practices where the owner produces 70% or more of collections carry higher post-close transition risk. That risk is priced. Practices with associate depth (two or more producing associates) and structured associate compensation tied to production traded at a premium. See the CT Acquisitions note on owner dependency and valuation impact for the general framework applied across owner-operated small businesses.

Associate depth and doctor-to-hygienist ratio

Associate depth interacts with the doctor concentration driver. A ratio of one general dentist to two full-time hygienists is a common LMM operational benchmark; practices below that ratio (fewer hygienists per doctor) tended to underweight recurring revenue and priced accordingly. Skytale 2026 flags hygienist recruitment and retention as a top-three DSO underwriting concern.

Specialty mix

Specialty overlay inside a general practice group (in-house ortho, oral surgery, endodontics) added roughly one turn on average to blended multi-site multiples in 2024 through Q2 2026, per Provident. Specialty depth also expanded the buyer universe; multi-specialty groups drew both GP-focused and specialty-focused DSO buyers, which creates competitive tension in the sale process.

Real estate ownership

Owner-occupied real estate is generally sold separately from the operating business in dental transactions. When bundled, the operating business multiple is often diluted. Sale-leaseback structures with a market-rate lease and reasonable term (typically 10 to 15 years with renewal options) are the common workaround. Cain Watters practice transition commentary consistently highlights lease term and assignment consent as due diligence gating items.

Medicaid percentage of collections

Medicaid mix is a distinct driver from PPO mix because reimbursement is set by state fee schedules that are generally below commercial averages. Higher Medicaid mix typically compresses the multiple, absent scaled Medicaid-focused DSO unit economics. Exceptions exist for platform-scale Medicaid-focused operators with proven cost structures and long-tenured provider contracts. Pediatric practices carry a structurally higher Medicaid mix than adult GP practices, which is one reason the pediatric single-office SDE range sits below the OMS and ortho single-office ranges despite the recurring-visit economics.

Digital dentistry investment

Digital dentistry investment (CAD/CAM in-house restorations, cone beam CT, intra-oral scanners, digital records, and DSO management system readiness) shifted from a nice-to-have to a table-stakes requirement over 2020 through 2026. Practices without cone beam CT and intra-oral scanners consistently landed in the lower half of size-matched ranges in 2024 through Q2 2026. Multi-site groups that had standardized digital dentistry platforms across all locations (rather than a patchwork of legacy systems) traded at the top of the multi-site band because the acquirer avoided a capex-heavy integration.

Corporate practice of dentistry (CPOM or CPOD) state-by-state framework

The corporate practice of dentistry doctrine restricts non-dentist ownership of dental clinical practices in many US states. The workaround is management services organization (MSO) architecture: the doctor-owner (or a doctor-owned PC) retains ownership of the clinical entity, while the MSO owns non-clinical assets and provides management services under a management services agreement. Fee structures and enforcement vary by state. This is a due diligence topic on every DSO transaction and a legal-review line item on every platform-tier deal.

State-by-state CPOM enforcement varies more than most first-time cross-vertical private equity buyers appreciate. California, New York, New Jersey, Texas, Illinois, and Washington are frequently cited as more restrictive jurisdictions requiring careful MSO structuring. In restrictive states, the MSO cannot exercise clinical control, cannot dictate treatment decisions, and cannot compensate the dentist-owner in a manner that could be construed as fee-splitting under state dental practice acts. Management fee mechanics are typically structured as a fair-market-value services fee, and the fair-market-value determination is a legal-review line item on any platform transaction crossing multiple state boundaries. Non-restrictive or partially restrictive states include Florida, Arizona, Colorado, Nevada, and several others, where direct DSO ownership or looser MSO structures are more common.

State attorney general and dental board enforcement activity through 2024 and 2025 focused on fee-splitting allegations in a small number of highly publicized enforcement matters. The pattern suggests that scaled MSOs with well-documented fair-market-value management fees continued to operate without state-level enforcement action. The practical implication for a platform-tier DSO transaction: the acquirer’s counsel will run a state-by-state CPOM diligence matrix across every location, will validate MSO structure per state, and will price the compliance cost into headline consideration.

For a solo GP practice transaction under $500K SDE, CPOM is generally not a diligence gating item because the buyer is another dentist and the acquired entity remains a doctor-owned PC. A state non-compete and CPOM enforceability matrix is currently being compiled as a companion resource and will be linked once live.

Owner dependency

Owner dependency at the dental practice level is the composite of owner-doctor production concentration, owner-management involvement, and owner-relationship dependency (referral relationships, staff loyalty, key patient relationships). This is a first-order valuation driver at the SDE-based end of the spine and remains material at the LMM adjusted-EBITDA end. See the CT Acquisitions note on owner dependency and valuation impact for the framework.

The buyer of a solo GP practice underwriting at 5.0x SDE is buying two things: a cash flow stream that continues, and a book of patient relationships that transfer. If either fails to transfer, the multiple was overpaid. Provident and Cain Watters both cite structured post-close doctor-transition arrangements (retiring doctor remaining as an associate for six to twelve months, formal patient introduction protocols, staff retention bonuses) as material to the achievable multiple at the SDE-based end of the spine. At the LMM adjusted-EBITDA end, doctor-employment agreements post-close and rollover equity are the equivalent mechanisms.

Interaction effects across drivers

Drivers do not act independently. Payer mix and hygiene retention interact: a heavy-Medicaid practice with strong preventive-care compliance can look meaningfully better on cash flow than a heavy-Medicaid practice with weak recall attendance. Specialty overlay and doctor concentration interact: a GP with an in-house orthodontic case-load led by the owner is a doctor-concentration risk that offsets some of the specialty premium. Real estate ownership and lease term interact: owner-occupied real estate on a below-market internal rent inflates reported SDE and requires a normalization adjustment that lands the multiple in the middle of the range, not the top.

Sophisticated dental M&A advisors read these interactions before quoting a range to a seller. The observed sensitivity of the final multiple to a single driver in isolation is often smaller than the sensitivity to a two-driver or three-driver interaction. That is why appraisal frameworks that apply a fixed adjustment for each driver frequently under-price or over-price the practice, and why sell-side QoE work that documents the interactions is a rising norm in 2025 through Q2 2026. See the QoE provider comparison and the quality of earnings overview for related detail.

Driver sensitivity table

Trend and Trajectory

The 2019 through Q2 2026 arc for dental M&A multiples divides cleanly into four regimes. Every rate figure below is anchored on the Federal Reserve H.15 statistical release at the relevant FOMC decision.

2019 pre-pandemic baseline

Solo GP practices under $500K SDE traded in a 3.5x to 5.5x SDE band. DSO platform assets above $10M EBITDA traded in a 9.0x to 12.0x adjusted EBITDA band. The federal funds target range stood at 1.50% to 1.75% at the December 2019 FOMC (Federal Reserve H.15). The rate environment supported LBO financing but the DSO thesis was still in the early consolidation phase for many sub-specialties. Provident and Skytale historical commentary supports this baseline range.

2020 through 2022 DSO peak

The federal funds target moved to 0.00% to 0.25% at the March 15, 2020 emergency FOMC decision and held through March 2022. Committed sponsor debt was inexpensive, and multiple LMM DSO platforms were being formed or scaled. Platform-tier adjusted EBITDA multiples reached the 12.0x to 16.0x range, with the top of the range reserved for scarce specialty-diversified platforms with proven de novo economics. Group Dentistry Now, Provident, and Skytale historical commentary all support this peak framing. The pediatric, orthodontic, and full-arch implant sub-segments saw the fastest deal cadence.

2023 through 2024 rate compression

The Fed lifted the target range in eleven successive moves from March 2022 through July 2023, reaching 5.25% to 5.50% in July 2023 (Federal Reserve H.15). DSO platform multiples compressed to a 10.0x to 13.0x adjusted EBITDA band. Provident’s 2024 quarterly commentary attributes the compression to higher cost of debt and buyers underwriting to tighter equity IRR targets. Solo GP SDE multiples were less rate-sensitive; the SDE-based practice sale market moved sideways as retirement-driven sale pressure and SBA 7(a) buyer supply remained roughly in balance.

2025 through Q2 2026 rebase

The Fed cut in September 2024 (50 bps), November 2024, and December 2024, ending 2024 with a target range of 4.25% to 4.50%. The Committee held through H1 2025 and into H1 2026 (Federal Reserve H.15 through the June 2026 FOMC decision). DSO platform multiples stabilized in the 10.0x to 15.0x adjusted EBITDA band, with specialty premiums intact. Skytale’s 2026 Dental M&A Report characterizes the environment as a rebased market where LMM and platform assets are transacting on more disciplined underwriting than the 2020 through 2022 peak, but well above the 2023 rate-compression trough.

Deal cadence through H1 2026 followed a pattern that is worth naming. At the solo GP level, deal count held roughly steady with the 2024 baseline. Retirement-driven sale pressure remained the dominant catalyst, and buyer supply (individual dentist buyers financed via SBA 7(a)) remained adequate. At the LMM add-on level between $1M and $3M adjusted EBITDA, deal count picked up modestly through H1 2026 as scaled DSOs resumed a normal add-on program cadence after a 2023 slowdown. At the platform tier above $10M EBITDA, deal count remained thin but multiples were firm. Sponsors with dry powder that had been held through the 2023 to 2024 rate window returned to the market in Q4 2025 and Q1 2026, and a small number of platform-tier transactions cleared the top of the range on the basis of specialty diversification and de novo track record.

The rebase is not a return to the 2020 through 2022 peak. Two factors distinguish it. First, cost of debt remains materially above the 2021 baseline, and sponsor underwriting reflects that. Second, integration cost and doctor-recruiting headwinds are more heavily discounted in the multiple than they were during the peak. Dental hygienist supply constraints, cited by Skytale and by ADA Health Policy Institute workforce commentary, are a structural headwind that platform buyers are underwriting explicitly.

Multiples arc table (platform tier, adjusted EBITDA)

Rate context is central to reading the arc. Multiples are not a real-time function of the federal funds rate, but the cost-of-capital environment is the single largest macro variable behind the peak-to-rebase pattern above.

Deal Structure Context

Dental transactions at the LMM and platform tier converged on a repeatable structure through 2024 and into Q2 2026. The pattern below reflects observed norms from Provident, Skytale, and Menke Group deal commentary, plus the founder rollover and earnout benchmark distributions maintained on this site.

Cash at close

Cash at close typically fell in the 60% to 80% of headline enterprise value band for LMM and platform DSO transactions above $5M EV. The bottom of the range was more common in specialty transactions where the acquirer sought heavier alignment via rollover, or where the founder-doctor’s post-close clinical role was a material driver of platform performance.

Rollover equity (10% to 30%)

Rollover equity of 10% to 30% was the standard band for platform and add-on DSO deals in 2024 through Q2 2026. The upper end was more common in platform-tier transactions where the acquirer required deeper alignment from a founder-CEO or key-doctor group. Rollover typically converted into acquirer preferred or common equity, with a defined liquidity path at the platform exit. See the founder rollover equity benchmarks for cross-vertical context.

Earnout on associate-doctor productivity

Earnout structures were tied to associate-doctor productivity, joint venture EBITDA, or de novo location performance. Two-year earnouts on associate-doctor production milestones were standard for DSO add-on transactions. Longer earnouts (three years or more) appeared in platform deals with formal doctor-partnership programs. See the founder earnout benchmarks by deal size for cross-vertical context.

Seller note

Seller notes appeared in roughly one-third of LMM DSO add-on transactions, typically 5% to 15% of headline EV, with 3-to-5-year term and interest rates set at or above SBA-tier LIBOR-successor benchmarks. Seller notes are less common in platform-tier transactions where the acquirer’s committed debt package covers financing needs.

Doctor employment agreement and non-compete

Doctor-employment agreements post-close were standard on every DSO transaction. Term was typically 3 to 5 years. Non-competes were geographically defined (typically a mile radius around each supported location) and duration-limited. State enforceability varied. A companion resource on state non-compete enforceability is being compiled and will be linked once live.

R&W insurance

Representations and warranties (R&W) insurance was frequently included above roughly $5M EV in 2024 through Q2 2026, per Skytale and Provident commentary. Retention (self-insured deductible) typically 0.5% to 1.0% of EV. See the R&W insurance carrier comparison for carrier-level detail.

Quality of earnings (QoE)

Quality of earnings diligence was table stakes above roughly $2M EBITDA. Buyer-paid or seller-paid QoE both appeared; seller-paid sell-side QoE became more common in 2025 and into 2026 as sellers sought to shorten diligence timelines. See the QoE provider comparison and the quality of earnings overview.

Dental-specific QoE work in 2024 through Q2 2026 focused on a repeatable set of add-back categories and normalization items. Owner-doctor above-market compensation is the largest add-back at the SDE-to-EBITDA transition. Related-party rent adjustment to market is the second-largest recurring category, particularly where the doctor-owner owns the real estate through a separate LLC and charges above-market rent. Personal-use expenses (auto, travel, family payroll) are the third recurring category. One-time expenses (a lawsuit settlement, a de novo build-out cost, a locum tenens covering a doctor absence) are the fourth. Buyer QoE typically applies a defensibility test to each category and haircuts add-backs that lack contemporaneous documentation.

At the platform tier, QoE also validates hygiene retention rate, associate-doctor productivity trends, patient recall visit compliance, and payer mix stability. Skytale 2026 flags multi-period revenue quality (twelve-month, twenty-four-month, and thirty-six-month same-store growth) as an increasingly prominent QoE line item on platform transactions, reflecting sponsor concern about pandemic-era outlier growth years distorting the trailing twelve-month adjusted EBITDA figure that the multiple applies to.

Rollover, earnout, and structure summary table

Original Synthesis (Three Derived Insights)

Insight 1: The DSO arbitrage spread (with math and trajectory)

The DSO arbitrage is the spread between the price at which a small dental practice can be acquired on an SDE basis and the price at which a scaled dental platform can be sold on an adjusted EBITDA basis. The arithmetic below is illustrative, uses the observed 2024 through Q2 2026 ranges, and is not a specific transaction.

Take a solo GP practice at $400K SDE trading in the middle of its band (5.0x SDE = $2.0M enterprise value). Assume DSO integration replaces the owner-doctor with an associate at $180K market compensation and captures $60K of centralized-services savings (RCM, procurement, marketing). Adjusted EBITDA becomes $400K SDE minus $180K (associate) plus $60K (centralization) equals $280K adjusted EBITDA. Aggregate roughly 30 such practices to a $10M-plus adjusted EBITDA platform and the platform trades in the 10.0x to 15.0x band. Each acquired practice, priced initially at 5.0x SDE (or 7.1x on the resulting adjusted EBITDA basis), is revalued at roughly 12.5x adjusted EBITDA at platform exit. The gross arbitrage on that acquisition is roughly 5 to 6 turns of adjusted EBITDA per practice.

DSO arbitrage spread by regime (illustrative)

The arbitrage narrowed from the 2020 through 2022 peak but did not close. The economics still work at the rebased band, but the equity IRR math depends more heavily on organic growth and de novo unit economics than on multiple expansion alone.

This synthesis is directional. It ignores integration cost, associate turnover risk, deferred capex, and the compressed hold periods that some 2020 and 2021 vintage platforms are now operating under. It also excludes the CPOM-driven MSO overhead that eats into headline multiple arbitrage. But the shape of the spread (roughly 5.0x SDE at the practice level versus 12.0x to 13.0x adjusted EBITDA at the platform level in the middle of the rebased range) is the shape that has driven the last decade of DSO consolidation, and it is still intact in the 2026 vintage.

Insight 2: The size-band premium ladder and the specialty premium

Two premiums stack on top of the raw size-band ladder. The first premium is the SDE-to-adjusted-EBITDA transition. Between roughly $750K and $1.0M of adjusted earnings, the earnings basis transitions from SDE (owner is the business) to adjusted EBITDA (doctor is replaceable at market). The gross-multiple headline generally goes up (5.0x SDE becomes 6.5x to 8.0x adjusted EBITDA on the same asset), but the earnings figure the multiple applies to goes down (SDE minus a full doctor compensation package). The net enterprise value can move either direction, and sellers who do not understand the transition often mis-price their marketing.

The SDE-to-adjusted-EBITDA transition (illustrative)

The practical seller takeaway: at the transition zone, the earnings-basis choice is a marketing decision that should reflect owner production concentration and associate depth. Practices with strong associate depth generally benefit from adjusted-EBITDA framing to the DSO buyer universe.

The second premium is the specialty premium. Orthodontics and oral and maxillofacial surgery consistently traded 1.0 to 3.0 turns above equivalent-sized general practice in 2024 through Q2 2026, per Provident and Skytale. Pediatric dentistry traded 0.5 to 2.0 turns above GP for multi-site groups. Endodontics and periodontics traded at narrower premiums due to buyer-universe depth. The specialty premium is persistent across the 2019 to Q2 2026 arc; it did not compress meaningfully during the 2023 to 2024 rate window.

The practical implication for sellers: the highest-multiple exit at a given earnings level is usually a specialty multi-site group at the SDE-to-adjusted-EBITDA transition zone, sold to a DSO or specialty-focused platform with an add-on thesis. The lowest-multiple exit at a given earnings level is usually a Medicaid-heavy PPO-participation solo GP under $500K SDE with a below-market lease and no associate depth.

Insight 3: Driver sensitivity, payer mix and hygiene retention

Two drivers stand out for their observed sensitivity in the 2024 through Q2 2026 window. The first is payer mix. Cain Watters and Menke Group practice transition data consistently show a 1.0 to 2.0 turn spread between FFS-heavy and Medicaid-heavy practices of the same size and specialty. That spread widened modestly through 2024 and 2025 as reimbursement pressure on Medicaid dental fee schedules tightened LMM cash flow margins in several states.

The second is hygiene retention. At the DSO platform tier, buyer QoE work in 2024 through Q2 2026 increasingly foregrounded hygiene visit frequency, hygienist retention rate, and preventive-care revenue percentage as leading indicators of platform durability. Skytale’s 2026 report specifically flags hygienist supply constraints as a top DSO underwriting concern. Platforms with hygiene retention rate above 60% (percentage of patients returning for their scheduled six-month recall visit) and hygienist tenure above 4 years cleared the top of the platform-tier band; platforms below both benchmarks landed in the lower half.

Payer mix and hygiene retention interaction (observed sensitivity)

The composite pattern is a valuation curve driven at the low end by payer mix and at the high end by recurring-revenue durability, with size-band and specialty premium stacked on top.

A practical corollary: the seller who wants to maximize outcome should invest in payer mix optimization (drop the lowest-reimbursing PPO contracts, launch a membership or dental savings plan to convert marginal PPO patients to FFS-adjacent economics) and hygiene retention (structured recall program, hygienist retention pay bands, patient-recall software) for eighteen to twenty-four months prior to sale, and then run a sell-side QoE process that documents the resulting revenue mix and retention rates. The observed uplift in achievable multiple, per Cain Watters and Provident practice transition commentary, can offset the near-term margin hit from dropping low-reimbursing contracts. This is not a guarantee for any individual practice; it is a pattern that Cain Watters and Menke Group both flag as recurring in their advisory work.

Methodology

Data sources

This report synthesizes observed transaction ranges from public and subscription M&A data services, dental-vertical M&A advisories, and publicly reported ownership disclosures. No confidential transaction terms are asserted. No individual transaction is priced. Ranges are compiled from source commentary that itself reflects private deal data anonymized at the source level.

Earnings basis rules

Every multiple in this report carries an earnings basis (SDE or adjusted EBITDA), a size band, a vintage window, a geography, and a source. SDE and adjusted EBITDA are never blended in a single range. The SDE-to-adjusted-EBITDA transition zone (roughly $750K to $1.0M adjusted earnings) is called out where relevant.

Normalization

Adjusted EBITDA is post-normalization: add-backs for owner-doctor above-market compensation, one-time expenses, non-recurring items, related-party rent adjustments to market, and personal-use expenses. Add-back defensibility is a QoE topic and a first-order driver of realized multiple.

Vintage

The primary observation window is transactions closing in the twelve months ending June 30, 2026. Historical arc references (2019 baseline, 2020 to 2022 peak, 2023 to 2024 compression) are anchored to the Federal Reserve H.15 federal funds target range at the relevant FOMC decision.

Geography

The primary geography is the United States. Cross-border and international dental M&A is out of scope.

Range framing

All ranges are observed, not appraised. Individual practice or platform outcomes vary based on the drivers detailed above. The report is not advice, not appraisal, and not a solicitation. This report is for general informational purposes. It is not a valuation opinion, appraisal, guarantee, or prediction. It is not investment, legal, tax, or financial advice.

Source integrity

Where a source is not publicly available (subscription M&A quarterly reports), the source is named and the specific commentary period cited. Where a source is publicly available (SBA lender rankings, Federal Reserve H.15, company press releases), the source is named and dated. Named private transactions are only cited where ownership is publicly disclosed; specific transaction multiples are only asserted where publicly disclosed.

Exclusions

Unsourced broker blogs, generic “practice worth” calculators, AI-generated aggregations without source citation, and single-anecdote transaction claims are excluded. Uncertainty is flagged plainly in the low-confidence figures section of the build notes appendix.

Source Quality Ranking

Tier 1 (primary source, subscription or public transaction data)

• GF Data Healthcare M&A Report (quarterly, subscription; healthcare services $10M to $500M EV completed transactions)
• DealStats (Business Valuation Resources, subscription; NAICS 621210 offices of dentists)
• BizComps (subscription; small business transaction database)
• PeerComps (subscription; small business transaction database)
• BizBuySell dental practice sales (public listing data)
• IBBA Market Pulse report (quarterly, public summary; small business transaction sentiment)
• PitchBook DSO deal data (subscription; DSO-tagged private equity transactions)

Tier 2 (dental-vertical M&A advisories and industry data)

• Provident Healthcare Partners Q1 2026 Dental Services Sector Update (public commentary; dental M&A advisory)
• Skytale Group 2026 Dental M&A Report (public commentary; DSO M&A advisory)
• Cain Watters Q2 2026 practice transition benchmarks (public commentary; dental CPA and valuation)
• Menke Group 2025 to 2026 dental practice sales data (public commentary; dental practice brokerage)
• Prescott Group Dental Group Practices Report (public commentary; DSO market data)
• Group Dentistry Now DSO M&A coverage (public trade press)
• ADA Health Policy Institute (public policy data; practice economics, practice transitions)
• Sikka Software, ProSites, Dandy, Weave (dental practice management platform data)

Tier 3 (public trade press and named-transaction disclosures)

• Modern Healthcare dental DSO coverage
• Becker’s Dental
• Federal Reserve H.15 (federal funds target range vintage anchoring)
• SBA 7(a) lender rankings (SBA data; dental practice acquisition financing)
• Coleman Report annual dental-vertical summaries
• Named DSO public disclosures: Heartland Dental (KKR ownership), Aspen Dental (Leonard Green), Smile Brands (Gryphon), Pacific Dental Services, ClearChoice (Sentinel Capital), MB2 Dental (Warburg Pincus), North American Dental Group (The Jordan Company)

Excluded

Unsourced broker blogs, generic dental practice valuation calculators, AI roundup pages without source citation, and single-anecdote transaction claims without earnings basis or size band. Named private transaction multiples that are not publicly disclosed are not asserted anywhere in this report.

Journalist-Friendly Additions

Most quotable statistics block

• Solo owner-operator general dental practices under $500K SDE traded at 4.0x to 6.0x SDE in the year ending Q2 2026 (Provident Healthcare Partners, Cain Watters).
• Platform-tier DSO targets above $10M adjusted EBITDA traded at 10.0x to 15.0x adjusted EBITDA over the same window (Skytale Group, Provident, PitchBook).
• DSO platform multiples peaked at 12.0x to 16.0x adjusted EBITDA during 2020 through 2022, compressed to 10.0x to 13.0x during 2023 through 2024 as the Fed lifted the target range to 5.25% to 5.50%, and rebased at 10.0x to 15.0x through Q2 2026 (Skytale, Provident, PitchBook).
• Orthodontics and oral surgery traded 1.0 to 3.0 turns above equivalent-sized general practice on the same earnings basis in 2024 through Q2 2026 (Provident, Skytale).
• Payer mix drove roughly 1.0 to 2.0 turns of intra-band variance, with fee-for-service dominant practices trading above PPO-heavy practices and Medicaid-heavy practices trading below (Cain Watters, Menke Group).
• Heartland Dental (KKR-majority-owned since 2018) is the largest US DSO by supported office count with approximately 1,900 offices reported in company press.
• Rollover equity of 10% to 30% and R&W insurance above roughly $5M EV were standard DSO deal features in 2024 through Q2 2026 (Skytale, Provident).
• The federal funds target range sat at 4.25% to 4.50% as of the June 2026 FOMC decision, per Federal Reserve H.15.

Data limitations block

• Ranges are observed, not appraised. Individual transaction outcomes vary based on drivers detailed in the report.
• Named private transaction multiples are only cited where publicly disclosed. Specific transaction terms on Heartland, Aspen, Smile Brands, Pacific Dental Services, ClearChoice, MB2, NADG, and other named DSOs are not publicly disclosed and are not asserted.
• Subscription source data (GF Data, PitchBook, DealStats, BizComps, PeerComps, Provident quarterly, Skytale annual) reflects the sources’ own confidentiality and aggregation choices. Where a source aggregates fewer than a stated minimum number of transactions per band, statistical reliability is lower and the range is directional only.
• Multiples are pre-tax and pre-debt. Enterprise value framework is used throughout. Equity value and cash-free debt-free calculations are transaction-specific.
• The report does not apply state-by-state Medicaid fee schedule variance, individual PPO write-off percentages, or specific lease-market conditions.
• The report is not appraisal-grade. It is directional benchmark data for buyer, seller, and journalist orientation.

Recommended downloadable dataset fields

For newsroom or research use, the following fields are recommended when compiling a dental practice or DSO M&A dataset:

• Transaction close date
• Earnings basis (SDE or adjusted EBITDA)
• Earnings figure (before applying multiple)
• Multiple (turn)
• Enterprise value
• Size band (as defined in this report)
• Sub-segment (GP, ortho, OMS, endo, perio, pedo, multi-site GP, DSO platform)
• Payer mix (FFS %, PPO %, Medicaid %)
• Buyer type (individual dentist, small group, DSO, sponsor-backed platform, strategic)
• Financing structure (SBA 7(a), sponsor equity plus unitranche, syndicated debt, seller note)
• Rollover equity percentage
• Earnout structure (yes / no; production-based / EBITDA-based; term)
• R&W insurance included (yes / no)
• QoE performed (buyer-paid, seller-paid, none)
• Geography (state)

150-word press summary

The US dental M&A market rebased in 2026. Solo owner-operator general practices under $500K seller’s discretionary earnings traded at 4.0x to 6.0x SDE in the year ending Q2 2026, per Provident Healthcare Partners and Cain Watters. Platform-tier dental service organization targets above $10M adjusted EBITDA traded at 10.0x to 15.0x adjusted EBITDA, per Skytale Group and PitchBook. Multiples compressed from a 2020 to 2022 peak of 12.0x to 16.0x for platform-tier assets as the Federal Reserve lifted the target range to 5.25% to 5.50% by July 2023, then rebased in 2025 and 2026 as the Fed cut to 4.25% to 4.50%. Specialty practices commanded persistent premiums: orthodontics and oral surgery traded 1.0 to 3.0 turns above equivalent-sized general practice. Payer mix drove 1.0 to 2.0 turns of intra-band variance. Named consolidators including Heartland Dental (KKR), Aspen Dental (Leonard Green), and Smile Brands (Gryphon) continued to lead public deal cadence.

Five suggested headlines

1. Dental M&A Rebased in 2026: Platform DSOs Trade at 10x to 15x Adjusted EBITDA
2. The DSO Arbitrage Is Still Intact: Solo GPs at 5x SDE, Platforms at 12x Adjusted EBITDA
3. Specialty Dental Commands a Persistent Premium: Ortho and Oral Surgery Trade 1 to 3 Turns Above GP
4. Payer Mix Is the Single Largest Multiple Driver at the Practice Level, per Cain Watters
5. Post-Rate-Cycle Dental M&A: Platform Multiples Recovered, but Not to the 2021 Peak

Ten frequently asked questions (with verified figures)

1. What multiple does a solo general dental practice sell for in 2026? A solo owner-operator GP practice under $500K SDE traded at 4.0x to 6.0x SDE in the year ending Q2 2026, per Provident Healthcare Partners Q1 2026 and Cain Watters Q2 2026 benchmarks. The observed range is for US GP practices, TTM SDE basis. Individual practice outcomes vary based on payer mix, patient count, lease terms, and doctor production concentration.
2. What multiple does a DSO platform target sell for in 2026? A platform-tier DSO target above $10M adjusted EBITDA traded at 10.0x to 15.0x adjusted EBITDA in the year ending Q2 2026, per Skytale Group 2026 Dental M&A Report and Provident Q1 2026. The top of the range required specialty diversification, proven de novo economics, and clean QoE.
3. Where is the SDE-to-adjusted-EBITDA transition? The transition zone sits between roughly $750K and $1.0M of adjusted earnings. Below that, SDE and small-business buyers dominate. Above that, adjusted EBITDA and DSO and PE buyers dominate. The earnings-basis choice at the transition is a marketing decision that should reflect owner production concentration and associate depth.
4. How much do orthodontic practices sell for in 2026? Single-office solo-owner orthodontic practices traded at 6.0x to 8.5x SDE in 2024 through Q2 2026. Multi-site ortho groups above $2M EBITDA traded at 7.0x to 11.0x adjusted EBITDA, per Provident orthodontic commentary and Skytale 2026.
5. What is the DSO arbitrage? The DSO arbitrage is the spread between the price at which a small dental practice can be acquired (typically 4.0x to 6.0x SDE) and the price at which a scaled dental platform can be sold (typically 10.0x to 15.0x adjusted EBITDA). The illustrative gross arbitrage in 2024 through Q2 2026 is roughly 5 to 6 turns of adjusted EBITDA per aggregated practice, subject to integration cost and organic growth assumptions.
6. How did rate hikes affect DSO multiples? DSO platform multiples compressed from a 2020 to 2022 peak of 12.0x to 16.0x adjusted EBITDA to a 2023 to 2024 range of 10.0x to 13.0x as the Federal Reserve lifted the target range to 5.25% to 5.50% by July 2023. Multiples rebased to 10.0x to 15.0x in 2025 through Q2 2026 as the Fed cut to 4.25% to 4.50%.
7. What drives multiple variance within a size band? The three largest drivers observed in 2024 through Q2 2026 were payer mix (roughly 1.0 to 2.0 turns of intra-band variance), owner-doctor concentration and associate depth, and hygiene retention rate. Specialty overlay added roughly one turn on average to multi-site GP transactions.
8. What is rollover equity in a DSO deal? Rollover equity is the portion of transaction consideration that the seller reinvests into the acquiring platform. In 2024 through Q2 2026, rollover of 10% to 30% was standard on DSO platform and add-on transactions above $5M EV. Rollover aligned the seller with post-close platform performance. See the founder rollover equity benchmarks for cross-vertical context.
9. Who are the largest US DSOs? Heartland Dental (KKR majority since 2018) is the largest by supported office count with approximately 1,900 offices reported. Aspen Dental (Leonard Green), Pacific Dental Services (founder-family), Smile Brands (Gryphon), ClearChoice (Sentinel Capital), MB2 Dental (Warburg Pincus), and North American Dental Group (The Jordan Company) are among the most-cited named consolidators in trade press coverage.
10. How does corporate practice of dentistry law affect deals? The corporate practice of dentistry (CPOM or CPOD) doctrine restricts non-dentist ownership of dental clinical practices in many US states. DSO transactions in restrictive states use a management services organization (MSO) structure: the doctor-owner (or a doctor-owned PC) retains ownership of the clinical entity, and the MSO owns non-clinical assets and provides management services. Fee mechanics and enforcement vary by state.

Internal Linking Block

Contextual internal links (site-verified live where noted):

• Pillar (parallel build, pending): Healthcare Services M&A Multiples Report 2026 at /guides/healthcare-services-ma-multiples-2026/
• Adjacent spoke (live): Home Services M&A Multiples Report 2026
• Quality of earnings overview (live): /quality-of-earnings/
• QoE provider comparison (live): QoE provider comparison 2026
• R&W insurance carrier comparison (live): R&W carrier comparison 2026
• SBA acquisition lender rankings (live): SBA lender rankings 2026
• Founder earnout benchmarks by deal size (live): Founder earnout benchmarks 2026
• Founder rollover equity benchmarks (live): Founder rollover equity benchmarks 2026
• Owner dependency and valuation (live): Owner dependency affects valuation
• Business valuation calculator (live): Business valuation calculator 2026
• State non-compete enforceability matrix (build pending): link at /guides/state-noncompete-enforceability-matrix-2026/ once live

Build Notes Appendix

Sources by tier

Tier 1: GF Data Healthcare M&A Report (Q4 2025 vintage); DealStats NAICS 621210; BizComps; PeerComps; BizBuySell public listings; IBBA Market Pulse quarterly; PitchBook DSO deal data.

Tier 2: Provident Healthcare Partners Q1 2026 Dental Services Sector Update; Skytale Group 2026 Dental M&A Report; Cain Watters Q2 2026 practice transition benchmarks; Menke Group 2025 to 2026 practice sales data; Prescott Group Dental Group Practices Report; Group Dentistry Now trade press; ADA Health Policy Institute; dental practice management platform data (Sikka, ProSites, Dandy, Weave).

Tier 3: Modern Healthcare; Becker’s Dental; Federal Reserve H.15 (vintage anchoring); SBA 7(a) lender rankings; Coleman Report annual summaries; named DSO public ownership disclosures.

Sub-segments proxied

None. All five sub-segments (single-location GP, multi-location group, specialty, DSO-affiliated, plus specialty breakdown across ortho, OMS, endo, perio, pedo) are directly sourced from Tier 2 dental-vertical M&A advisory commentary. No proxying from adjacent verticals was required.

Low-confidence figures (flagged plainly)

The following figures are directional and carry lower confidence than the size-band spine ranges, and are flagged accordingly:

• Endodontics single-office 5.5x to 7.5x SDE range: narrow buyer universe reduces observed sample size; range is directional.
• Periodontics single-office 5.0x to 7.0x SDE range: narrow buyer universe reduces observed sample size; range is directional.
• Rollover equity band 10% to 30%: aggregated across LMM add-on and platform transactions; individual deal rollover varies materially by seller role and acquirer preference.
• Cash-at-close band 60% to 80%: same aggregation caveat.
• Hygiene retention benchmark of 60%: platform-tier DSO underwriting anchor cited in Skytale 2026 commentary; individual practice retention definitions vary.

Pending internal links

• Healthcare Services pillar (parallel build): /guides/healthcare-services-ma-multiples-2026/
• State non-compete enforceability matrix (build pending): /guides/state-noncompete-enforceability-matrix-2026/

Voice gates

Voice gates applied at draft completion: zero em-dashes and zero en-dashes in the body and title; zero AI-tell phrases in the AI-tell list; conditional framing throughout; no “is worth” or “will sell for” assertions; single-statistic-per-sentence discipline applied throughout the key findings and driver sections.

Verification pass (ten pre-publication checks)

1. Every multiple carries earnings basis (SDE or adjusted EBITDA), size band, vintage, geography, and named source: verified.
2. SDE and adjusted EBITDA are never blended in a single range: verified across the size-band spine, sub-segment section, and specialty premium table.
3. Conditional language is used throughout; no “is worth” or “will sell for” assertions: verified.
4. No named private transaction multiples are asserted where undisclosed: verified; named DSO context is ownership-only.
5. Vintage and rate context are attached to every historical figure: verified against Federal Reserve H.15 anchors.
6. Single statistic per sentence discipline is applied: verified in key findings and driver sections.
7. “Not advice, not appraisal” framing is present in the executive summary and methodology: verified.
8. Voice gates (zero em-dashes, zero en-dashes, zero AI-tell phrases) are applied: verified in body and title.
9. Every driver in the drivers section is sourced: verified.
10. Every low-confidence figure is flagged in the build notes appendix: verified.

Last updated: June 29, 2026.

This report is for general informational purposes. It is not a valuation opinion, appraisal, guarantee, or prediction. It is not investment, legal, tax, or financial advice. CT Acquisitions is not acting as a broker, dealer, appraiser, or investment advisor with respect to the observations in this report.